Vemurafenib
- TRADE NAME: Zelboraf (Roche)
- INDICATIONS: Melanoma (metastatic or unresectable)
- CLASS: BRAF inhibitor
- HALF-LIFE: 57 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amoxapine, Arsenic, Atazanavir, Carbamazepine, Clarithromycin, CYP substrates, Dolasetron, Efavirenz, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Pazopanib, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, Telavancin, Telithromycin, Voriconazole, Warfarin
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of vemurafenib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/01/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric